Hemo - Trading on Ortex8 Feb 2024 12:28
Hemogenyx Pharmaceuticals, operating under the ticker HEMO,
appears to stand out within the biotech sector with a significant upward move of 90.25% more than its peers over the past month.
The firm's performance also reflects this surge with a 7-day price increase of 17.91% and a year-to-date uptick of 71.74%,
while its Relative Strength Index (RSI) pushes towards the higher end at 78.97.
Trading activity for HEMO has surged with the last trading day's volume reaching almost 9.8 million shares—64.4% above its three-month average.
To add -
3 month chart since Prevail got involved in September shows a strong upward trend
Prevail getting involved in sept was the solid underpinning to the future of Hemo & stock re rate - regarding CAR T - imo
Clinical is the stock value napalm imo & as per Vlads previous podcast he also noted the increased valuation.
Prevail RNS paragraph & carry’s clout -
Mary Schaheen, President of Prevail Partners, stated: "Everyone at our fund is confident in the growth and success of Hemogenyx Pharmaceuticals as they develop CAR-T cells to target acute myeloid leukemia. Furthermore, Hemogenyx Pharmaceuticals has a seasoned management team with the expertise to accelerate the company to a significant value inflection point through the completion of its planned clinical trial."
Prevail got involved at a premium - obviously can see the potential return on CAR T menu
Next week RNS update imo & an absolute whacker
Need volume first
Fetch the Top shelf Grog